Last update
3/18/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
USERS' SCORE
Good
Based on 3 Reviews
8.4
Supplement Facts
Serving Size: 1 Veggie Capsule
Serving Per Container: 60
Amount Per Serving
%DV
Vitamin K2 (from MenaQ7® Menaquinone, MK-7)
45 mcg
38%
Top Medical Research Studies
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
Most Useful Reviews
9
Cardiovascular benefits
A great product with quality ingredients and high dosage, providing significant cardiovascular benefits.
Read More
7.5
Good health
1 people found this helpful
I usually buy California Gold Nutrition Vitamin K2 but this was my alternative. I have taken K2 for over fifteen years and my cardiovascular health remains good.
Read More
7.5
Avoids calcification
Take it with Vitamin D3 to prevent cardiovascular calcification.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
- All Researches
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Read More
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
7
Atrial fibrillation treatment effectiveness confirmed
We explored how closely real-world patients with atrial fibrillation matched the results from major trials using apixaban and rivaroxaban compared to vitamin K antagonists. By tracking patients from the GARFIELD-AF registry, we observed that these real-life outcomes on stroke prevention, bleeding, and mortality closely mirrored those of the original trials. The study found that while the real-world patients had lower cardiovascular risks, the efficacy and safety of the treatments remained strong and comparable. This demonstrates that the findings from the ARISTOTLE and ROCKET AF trials are relevant in everyday clinical settings.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9
Cardiovascular benefits
A great product with quality ingredients and high dosage, providing significant cardiovascular benefits.
Read More
7.5
Good health
1 people found this helpful
I usually buy California Gold Nutrition Vitamin K2 but this was my alternative. I have taken K2 for over fifteen years and my cardiovascular health remains good.
Read More
7.5
Avoids calcification
Take it with Vitamin D3 to prevent cardiovascular calcification.
Read More
Frequently Asked Questions
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
References
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. 10.1007/s11739-025-03922-6
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. 10.1007/s11239-025-03067-5
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. 10.1161/JAHA.124.038834
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
Data last updated:
